After several challenging quarters, Regeneron's sales growth is rebounding. In the first quarter, the company's revenue rose ...
Odyssey Therapeutics secured a valuation of $899.9 million after its shares rose 11.1% in their Nasdaq debut on Friday, ...
Investor's Business Daily on MSN
Why these four biotech stocks prove that follow-on entries still pop up in stock market leaders
AnaptysBio recorded $234 million in sales over the past four quarters.
Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.
A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout ...
The biotech landscape of 2026 is defined by a convergence of forces that are no longer theoretical but are actively reshaping how drugs are discovered, tested, and approved. From the FDA's formal ...
Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%.
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, ...
May 7 (Reuters) - Biopharmaceutical company Odyssey Therapeutics has raised $279 million in its upsized U.S. initial ...
The Manus Biotech Facility had a groundbreaking on Friday for a new expansion. According to organizers, the expansion will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results